Skip to content
Back to meeting Original
ecancer· @ecancer · X·· 1 day agoScore70

dostarlimab

Body · original

AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉https://ow.ly/wqVQ5100Vg6 @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer

19 views · 0 likes · 0 reposts · 0 replies

Conference abstracts
1270Pmatched by Gynaecological cancers

Differential immune profiling of short- and long-responders to dostarlimab in recurrent or advanced mismatch repair-deficient endometrial cancer

https://esmocongress.esmo.org
2877ROmatched by Rapid oral 1: Gastrointestinal tumour, upper digestive

Watch-and-wait (W&W) strategy for dostarlimab in localized deficient dMMR/MSI-H gastroesophageal adenocarcinoma (GEA): Results from the first interim analysis of the GERCOR-GONO DEWI phase II study

https://esmocongress.esmo.org

Source: ecancer · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.